← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Psychogenics, Inc.
Tarrytown, NY
$90,296,227
Total funding
28
Grants
Funding over time
peak $12.8M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$90,296,227 · 28
By mechanism
N01$73,175,060 · 2
R43$8,188,240 · 16
R44$6,364,959 · 5
R41$2,567,968 · 5
Investigators at Psychogenics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Largest grants
SCREENING OF INVESTIGATIONAL AGENTS THROUGH THE NINDS PRECLINICAL SCREENING PLATFORM FOR PAIN (PSPP)$12,383,618
N01 · FY2022 · DA
SCREENING OF INVESTIGATIONAL AGENTS THROUGH THE NINDS PRECLINICAL SCREENING PLATFORM FOR PAIN (PSPP)$11,772,171
N01 · FY2024 · DA
SCREENING OF INVESTIGATIONAL AGENTS THROUGH THE NINDS PRECLINICAL SCREENING PLATFORM FOR PAIN (PSPP)$10,891,025
N01 · FY2021 · DA
SCREENING OF INVESTIGATIONAL AGENTS THROUGH THE NINDS PRECLINICAL SCREENING PLATFORM FOR PAIN (PSPP)$9,482,040
N01 · FY2025 · DA
SCREENING OF INVESTIGATIONAL AGENTS THROUGH THE NINDS PRECLINICAL SCREENING PLATFORM FOR PAIN (PSPP)$9,216,959
N01 · FY2023 · DA
SCREENING OF INVESTIGATIONAL AGENTS THROUGH THE NINDS PRECLINICAL SCREENING PLATFORM FOR PAIN (PSPP)$8,339,730
N01 · FY2020 · DA
SCREENING OF INVESTIGATIONAL AGENTS THROUGH THE NINDS PRECLINICAL SCREENING PLATFORM FOR PAIN (PSPP)$5,825,160
N01 · FY2019 · DA
PSPP - IDENTIFICATION AND VALIDATION OF NOVEL PAIN RELATED ENDPOINTS, NOVEL ANIMAL MODELS OF PAIN AND PROFILING OF INVESTIGATIONAL AGENTS IN RODENT AND NON-RODENT [EXCLUDING (NHP)] SPECIES$3,124,762
N01 · FY2019 · DA
TARGET ENGAGEMENT OF INVESTIGATIONAL AGENTS IN PSPP$2,139,595
N01 · FY2023 · DA
Predictive Smoking Cessation Preclinical Battery$915,977
R44 · FY2015 · DA
Predictive Smoking Cessation Preclinical Battery$829,176
R44 · FY2012 · DA
Predictive Smoking Cessation Preclinical Battery$691,074
R44 · FY2014 · DA
Highthroughput analysis of behavior for CNS applications$567,245
R44 · FY2003 · MH
EEG Signature Analysis for Drug Repurposing for Rare Diseases$560,641
R44 · FY2024 · MH
Machine Learning Phenotypic De Novo Drug Design$499,946
R43 · FY2024 · MH
Machine Learning Phenotypic De Novo Drug Design$499,946
R43 · FY2023 · MH
Development of a Drug Candidate for the Treatment of Agitation in Alzheimer's Disease$495,699
R44 · FY2025 · AG
EEG Signature Analysis for Drug Repurposing for Rare Diseases$460,234
R44 · FY2025 · MH
High Throughput in Vivo Drug Discovery - Phase II$450,000
R44 · FY2008 · MH
High Throughput in Vivo Drug Discovery - Phase II$450,000
R44 · FY2010 · MH